Contribute Try STAT+ Today

After some very public cajoling, executives from some of the world’s largest drug makers have now agreed to testify about drug pricing at a Senate hearing later this month.

Of course, they would be foolish not to do so. The Senate Finance Committee leadership is not especially friendly to the pharmaceutical industry, which is already under siege. Showing up is simply smart politics in the face of proposals and legislation that could change the way they do business.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Why does Big Pharma price life saving medication like insulin, or medication older Americans take like Restasis so high? My insurance doesn’t cover these drugs needed to live, and I can’t afford them

  • Ed: All questions will be gold plated as each legislator would have deposited the necessary monies to pacify the question.

    How can Gilead rape the US based patient asking $1,000 per day when they ask patient in India about $10 per day?

    Remember what happened to Januvia (gliptin) in India. They tried to sell in the largest diabetic population country. Even the filthy rich won’t buy. They were content with Metformin. Merck finally lowered the price to make it affordable even for the rich.

  • Let me play the sage and predict that this pithy and truthful answer will not be hear, actually 2 of them.
    First, “we raise the prices because we can.”
    Second, “we set new drug prices high to avoid leaving money on the table – we can’t be expected to do that, can we?”

Comments are closed.